5 Comments
 
Most Helpful

Theoretically the DCF is the most "correct" valuation methodology, since we should be able to determine the value of anything by finding the net present value of its future cash flows. Notice how I said "most correct" and not best. When you are valuing a company, the best valuation methodology is the one that provides the most accurate estimate. Some companies are not market comparable, and trading comps are simply useless. Other companies such as a biotech or tech startups have unpredictable cash flows (kind of hard to find the NPV when you can't properly predict future cash flows; a probability weighted DCF can be used for these companies in some cases). FIG has similar issues due to the use of debt and net working capital in their balance sheet, so a DCF is also not the best approach here.

All in all, a mixture of different valuation methodologies and common sense is what we consider "best". Some other methodologies include: LBO analysis, sum of the parts, NAV (net asset value) etc.

Another thing here, there is no relationship among DCF, trading comps, and precedent transaction comps that always holds, but transaction comps tend to give you a higher valuation due to the control premium built into acquisition (a control premium is any amount paid by the buyer in excess of the target's actual value – e.g., you'll usually see deals where the strategic buyer pays $X in excess of the target's share price).

 

Iusto soluta id modi. Facere et deleniti consequatur laboriosam. Quae enim sed voluptatem inventore optio quisquam sed. Vel suscipit sequi qui magnam illum ratione repudiandae ex. Beatae corporis voluptatem labore quia et voluptatibus. Rerum omnis magni voluptatem sapiente ut sit. Aliquid dolor consequatur autem qui suscipit.

Voluptatibus velit ut aliquid optio ratione ex quae. Accusantium reiciendis eaque tempora. Dicta non qui occaecati id dignissimos sunt quis quas.

Et sint doloribus quae natus totam dolores iusto. Et voluptatem voluptatem et in ut fuga a. Consequatur necessitatibus ut natus. Nihil nesciunt molestiae quae consequuntur a voluptas unde.

Molestias exercitationem ut aspernatur distinctio voluptas. Atque sit temporibus voluptas libero quasi molestias qui. Qui officia sed exercitationem inventore aliquam.

Career Advancement Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • JPMorgan 01 98.4%
  • Guggenheim Partners 02 97.9%
  • Morgan Stanley 06 97.4%

Overall Employee Satisfaction

November 2026 Investment Banking

  • Moelis & Company No 99.5%
  • Morgan Stanley 02 99.0%
  • Evercore 01 98.4%
  • Banco Santander 04 97.9%
  • BMO Capital Markets 13 97.4%

Professional Growth Opportunities

November 2026 Investment Banking

  • Evercore 01 99.5%
  • Moelis & Company 01 99.0%
  • Morgan Stanley 05 98.4%
  • Goldman Sachs 01 97.9%
  • JPMorgan No 97.4%

Total Avg Compensation

November 2026 Investment Banking

  • Vice President (17) $409
  • Associates (58) $261
  • 3rd+ Year Analyst (8) $210
  • 2nd Year Analyst (29) $183
  • Intern/Summer Associate (16) $161
  • 1st Year Analyst (84) $151
  • Intern/Summer Analyst (77) $101
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
kanon's picture
kanon
99.0
3
BankonBanking's picture
BankonBanking
99.0
4
Secyh62's picture
Secyh62
99.0
5
DrApeman's picture
DrApeman
98.9
6
Betsy Massar's picture
Betsy Massar
98.9
7
GameTheory's picture
GameTheory
98.9
8
CompBanker's picture
CompBanker
98.9
9
dosk17's picture
dosk17
98.9
10
numi's picture
numi
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”